Logo image of BPMC

BLUEPRINT MEDICINES CORP (BPMC) Stock Fundamental Analysis

NASDAQ:BPMC - Nasdaq - US09627Y1091 - Common Stock - Currency: USD

127.96  -0.25 (-0.19%)

After market: 127.96 0 (0%)

Fundamental Rating

4

Taking everything into account, BPMC scores 4 out of 10 in our fundamental rating. BPMC was compared to 559 industry peers in the Biotechnology industry. BPMC may be in some trouble as it scores bad on both profitability and health. BPMC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year BPMC has reported negative net income.
BPMC had a negative operating cash flow in the past year.
BPMC had negative earnings in 4 of the past 5 years.
In the past 5 years BPMC reported 4 times negative operating cash flow.
BPMC Yearly Net Income VS EBIT VS OCF VS FCFBPMC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

BPMC has a better Return On Assets (-13.03%) than 82.47% of its industry peers.
Looking at the Return On Equity, with a value of -45.52%, BPMC is in the better half of the industry, outperforming 67.62% of the companies in the same industry.
Industry RankSector Rank
ROA -13.03%
ROE -45.52%
ROIC N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
BPMC Yearly ROA, ROE, ROICBPMC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 96.48%, BPMC belongs to the top of the industry, outperforming 96.24% of the companies in the same industry.
In the last couple of years the Gross Margin of BPMC has grown nicely.
BPMC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
BPMC Yearly Profit, Operating, Gross MarginsBPMC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BPMC has more shares outstanding
Compared to 5 years ago, BPMC has more shares outstanding
Compared to 1 year ago, BPMC has a worse debt to assets ratio.
BPMC Yearly Shares OutstandingBPMC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BPMC Yearly Total Debt VS Total AssetsBPMC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

BPMC has an Altman-Z score of 3.43. This indicates that BPMC is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BPMC (3.43) is better than 75.49% of its industry peers.
BPMC has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.01, BPMC is not doing good in the industry: 77.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Altman-Z 3.43
ROIC/WACCN/A
WACC16.16%
BPMC Yearly LT Debt VS Equity VS FCFBPMC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

BPMC has a Current Ratio of 2.80. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.80, BPMC is not doing good in the industry: 66.91% of the companies in the same industry are doing better.
A Quick Ratio of 2.75 indicates that BPMC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.75, BPMC is doing worse than 65.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.75
BPMC Yearly Current Assets VS Current LiabilitesBPMC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.24% over the past year.
BPMC shows a strong growth in Revenue. In the last year, the Revenue has grown by 99.14%.
BPMC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.23% yearly.
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%

3.2 Future

The Earnings Per Share is expected to grow by 28.63% on average over the next years. This is a very strong growth
BPMC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.27% yearly.
EPS Next Y74.86%
EPS Next 2Y50.77%
EPS Next 3Y46.79%
EPS Next 5Y28.63%
Revenue Next Year41.61%
Revenue Next 2Y37.01%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BPMC Yearly Revenue VS EstimatesBPMC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
BPMC Yearly EPS VS EstimatesBPMC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 10 -10 20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BPMC. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 123.32 indicates a quite expensive valuation of BPMC.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BPMC indicates a rather cheap valuation: BPMC is cheaper than 88.19% of the companies listed in the same industry.
BPMC is valuated expensively when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 123.32
BPMC Price Earnings VS Forward Price EarningsBPMC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPMC Per share dataBPMC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BPMC's earnings are expected to grow with 46.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.77%
EPS Next 3Y46.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BPMC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEPRINT MEDICINES CORP

NASDAQ:BPMC (6/13/2025, 8:00:02 PM)

After market: 127.96 0 (0%)

127.96

-0.25 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners109.31%
Inst Owner Change3.61%
Ins Owners0.84%
Ins Owner Change3.5%
Market Cap8.26B
Analysts80
Price Target127.67 (-0.23%)
Short Float %8.88%
Short Ratio3.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.05%
Min EPS beat(2)-38.05%
Max EPS beat(2)-10.05%
EPS beat(4)2
Avg EPS beat(4)0.22%
Min EPS beat(4)-38.05%
Max EPS beat(4)39.24%
EPS beat(8)6
Avg EPS beat(8)7.49%
EPS beat(12)9
Avg EPS beat(12)6.42%
EPS beat(16)11
Avg EPS beat(16)-9.61%
Revenue beat(2)0
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-5.77%
Max Revenue beat(2)-1.61%
Revenue beat(4)1
Avg Revenue beat(4)5.58%
Min Revenue beat(4)-5.77%
Max Revenue beat(4)30.77%
Revenue beat(8)5
Avg Revenue beat(8)10.01%
Revenue beat(12)8
Avg Revenue beat(12)15.3%
Revenue beat(16)11
Avg Revenue beat(16)15.01%
PT rev (1m)-0.27%
PT rev (3m)-1.18%
EPS NQ rev (1m)-1.25%
EPS NQ rev (3m)-35.71%
EPS NY rev (1m)0%
EPS NY rev (3m)17.38%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)-2.4%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-0.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 123.32
P/S 14.7
P/FCF N/A
P/OCF N/A
P/B 24.15
P/tB 24.15
EV/EBITDA N/A
EPS(TTM)-3.22
EYN/A
EPS(NY)1.04
Fwd EY0.81%
FCF(TTM)-2.34
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS8.7
BVpS5.3
TBVpS5.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.03%
ROE -45.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.48%
FCFM N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.61%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.75
Altman-Z 3.43
F-Score3
WACC16.16%
ROIC/WACCN/A
Cap/Depr(3y)80.73%
Cap/Depr(5y)67.67%
Cap/Sales(3y)3.9%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
EPS Next Y74.86%
EPS Next 2Y50.77%
EPS Next 3Y46.79%
EPS Next 5Y28.63%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%
Revenue Next Year41.61%
Revenue Next 2Y37.01%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%
EBIT growth 1Y60.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.02%
EBIT Next 3Y49.05%
EBIT Next 5Y35.74%
FCF growth 1Y69.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.45%
OCF growth 3YN/A
OCF growth 5YN/A